

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 October 2023 (19.10.2023)



(10) International Publication Number
WO 2023/201362 A2

- (51) International Patent Classification:
C12N 15/11 (2006.01) A61K 31/712 (2006.01)
- (21) International Application Number:
PCT/US2023/065812
- (22) International Filing Date:
14 April 2023 (14.04.2023)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/330,797 14 April 2022 (14.04.2022) US
- (71) Applicant: **ARO BIOTHERAPEUTICS COMPANY**
[US/US]; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US).
- (72) Inventors: **KULKARNI, Swapnil**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **ADDIS, Russell**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **NADLER, Steven**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **XIN, Yao**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **DRUZINA, Zhanna**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **O'NEIL, Karyn**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US).

19106 (US). **KOLAKOWSKI, Robert**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **ANDERSON, Stephen**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US).

(74) Agent: **LOTFI, Sima** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: FN3 DOMAIN-SIRNA CONJUGATES WITH ENZYME REPLACEMENT THERAPY




FIG. 1

(57) Abstract: The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, in combination with enzyme replacement therapies, as well as methods of making and using the same.

WO 2023/201362 A2

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*